drugset / Trial / NCT04740671

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

NCT04740671

Phase 3 Completed 410 enrolled Shanghai Henlius Biotech
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the efficacy and safety of HLX04-O administered by intravitreal injection (IVT) with ranibizumab in patients with active wAMD.

Timeline

Start
2021-07-01
Primary completion
2024-12-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody Intravitreal
Comparator Ranibizumab Monoclonal antibody